August 10, 2016
Kissei Pharmaceutical and JCR Pharmaceuticals said on August 9 that a PIII clinical study has gotten underway for a biosimilar version of Nesp (darbepoetin alfa), Kyowa Hakko Kirin’s long-acting erythropoiesis-stimulating agent, for the treatment of renal anemia. The two companies...read more